Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

BACKGROUND: Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimens in the Lake Victoria Basin of Tanza...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Infect Dis
Main Authors: Anywaine, Zacchaeus, Whitworth, Hilary, Kaleebu, Pontiano, Praygod, George, Shukarev, Georgi, Manno, Daniela, Kapiga, Saidi, Grosskurth, Heiner, Kalluvya, Samuel, Bockstal, Viki, Anumendem, Dickson, Luhn, Kerstin, Robinson, Cynthia, Douoguih, Macaya, Watson-Jones, Deborah
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Major Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548900/
https://ncbi.nlm.nih.gov/pubmed/30796818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiz070
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados